Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0536-y. [Epub ahead of print]

PMID:
31089280
2.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
3.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, Gastinne T, Le Bris Y, Lok A, Bonnet A, Le Gouill S, Moreau P, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2019 Mar 27. pii: S1083-8791(19)30209-5. doi: 10.1016/j.bbmt.2019.03.025. [Epub ahead of print]

PMID:
30928627
4.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.

Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14.

PMID:
30874851
5.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.

PMID:
30874850
6.

Eltrombopag induces major non-toxic hypersiderraemia.

Caillon H, Peterlin P, Chevallier P, Guillaume T, Lebourgeois A, Garnier A, Ropert-Bouchet M, Dejoie T.

Br J Haematol. 2019 Mar 15. doi: 10.1111/bjh.15863. [Epub ahead of print] No abstract available.

PMID:
30873599
7.

Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.

Willem C, Makanga DR, Guillaume T, Maniangou B, Legrand N, Gagne K, Peterlin P, Garnier A, Béné MC, Cesbron A, Le Bourgeois A, Chevallier P, Retière C.

J Immunol. 2019 Apr 1;202(7):2141-2152. doi: 10.4049/jimmunol.1801489. Epub 2019 Feb 20.

PMID:
30787107
8.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P.

Haematologica. 2019 Feb 7. pii: haematol.2018.207118. doi: 10.3324/haematol.2018.207118. [Epub ahead of print]

9.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

10.

Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.

Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Grégoire M, Pichinuk E, Rubinstein DB, Wreschner DH.

Exp Hematol. 2019 Feb;70:97-108. doi: 10.1016/j.exphem.2018.12.002. Epub 2018 Dec 26.

PMID:
30593830
11.

Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.

Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Bonnet A, Béné MC, Gouill SL, Moreau P, Kraeber-Bodéré F, Chevallier P.

Biol Blood Marrow Transplant. 2019 May;25(5):906-911. doi: 10.1016/j.bbmt.2018.11.019. Epub 2018 Nov 24.

PMID:
30481598
12.

A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.

Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, Guillaume T, Le Bourgeois A, Debord C, Godon C, Le Bris Y, Theisen O, Kroschinsky F, Moreau P, Béné MC, Platzbecker U, Eveillard M.

Br J Haematol. 2018 Dec;183(5):736-746. doi: 10.1111/bjh.15626. Epub 2018 Nov 8.

PMID:
30406952
13.

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.

Chevallier P, Peterlin P, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Le Bris Y, Béné MC, Le Gouill S, Moreau P, Guillaume T.

Oncotarget. 2018 Sep 11;9(71):33528-33535. doi: 10.18632/oncotarget.26083. eCollection 2018 Sep 11.

14.

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.

Peterlin P, Guillaume T, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Gallas P, Touzeau C, Gastinne T, Lok A, Thomare P, Chauvin C, Le Gouill S, Moreau P, Chevallier P.

Leuk Res Rep. 2018 Jan 17;9:16-17. doi: 10.1016/j.lrr.2018.01.002. eCollection 2018. No abstract available.

15.

Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Retière C, Willem C, Guillaume T, Vié H, Gautreau-Rolland L, Scotet E, Saulquin X, Gagne K, Béné MC, Imbert BM, Clemenceau B, Peterlin P, Garnier A, Chevallier P.

Oncotarget. 2018 Jan 27;9(14):11451-11464. doi: 10.18632/oncotarget.24328. eCollection 2018 Feb 20.

16.

Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide.

Garnier A, Delbos F, Guillaume T, Peterlin P, Le Bourgeois A, Béné MC, Le Bris Y, Malard S, Duquesne A, Gauvrit I, Moreau P, Cesbron A, Chevallier P.

Bone Marrow Transplant. 2018 Aug;53(8):1044-1047. doi: 10.1038/s41409-018-0107-7. Epub 2018 Feb 1. No abstract available.

PMID:
29391525
17.

Deconditioning, fatigue and impaired quality of life in long-term survivors after allogeneic hematopoietic stem cell transplantation.

Dirou S, Chambellan A, Chevallier P, Germaud P, Lamirault G, Gourraud PA, Perrot B, Delasalle B, Forestier B, Guillaume T, Peterlin P, Garnier A, Magnan A, Blanc FX, Lemarchand P.

Bone Marrow Transplant. 2018 Mar;53(3):281-290. doi: 10.1038/s41409-017-0057-5. Epub 2017 Dec 21.

18.

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P.

Haematologica. 2018 Apr;103(4):e143-e146. doi: 10.3324/haematol.2017.181404. Epub 2017 Dec 21. No abstract available.

19.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, de Latour RP.

Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.

20.

Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.

Peterlin P, Chauvin C, Le Gouill S, Pere M, Dalichampt M, Guillaume T, Garnier A, Paré M, Le Bourgeois A, Moreau P, Chevallier P, Deslandes G, Gastinne T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01746-17. doi: 10.1128/AAC.01746-17. Print 2018 Feb.

21.

Quality control in cone-beam computed tomography (CBCT) EFOMP-ESTRO-IAEA protocol (summary report).

de Las Heras Gala H, Torresin A, Dasu A, Rampado O, Delis H, Hernández Girón I, Theodorakou C, Andersson J, Holroyd J, Nilsson M, Edyvean S, Gershan V, Hadid-Beurrier L, Hoog C, Delpon G, Sancho Kolster I, Peterlin P, Garayoa Roca J, Caprile P, Zervides C.

Phys Med. 2017 Jul;39:67-72. doi: 10.1016/j.ejmp.2017.05.069. Epub 2017 Jun 9.

PMID:
28602688
22.

Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults.

Illiaquer M, Imbert-Marcille BM, Guillaume T, Planche L, Rimbert M, Bressollette-Bodin C, Le Bourgeois A, Peterlin P, Garnier A, Le Houerou C, Moreau P, Mohty M, Chevallier P.

J Clin Virol. 2017 Aug;93:30-36. doi: 10.1016/j.jcv.2017.05.019. Epub 2017 May 31.

PMID:
28601677
23.

Treating lung cancer with dynamic conformal arc therapy: a dosimetric study.

Peterlin P, Stanič K, Méndez I, Strojnik A.

Radiat Oncol. 2017 Jun 2;12(1):93. doi: 10.1186/s13014-017-0823-y.

24.

Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016).

Bourcier J, Heudes PM, Morio F, Gastinne T, Chevallier P, Rialland-Battisti F, Garandeau C, Danner-Boucher I, Le Pape P, Frampas E, Moreau P, Defrance C, Peterlin P.

Mycoses. 2017 Aug;60(8):526-533. doi: 10.1111/myc.12624. Epub 2017 Apr 21.

PMID:
28429890
25.

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.

Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2017 Jun;96(6):943-950. doi: 10.1007/s00277-017-2981-2. Epub 2017 Apr 3.

PMID:
28374163
26.

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Lestang E, Peterlin P, Le Bris Y, Dubruille V, Delaunay J, Godon C, Theisen O, Blin N, Mahe B, Gastinne T, Garnier A, Touzeau C, Voldoire M, Bene MC, Le Gouill S, Milpied N, Mohty M, Moreau P, Guillaume T, Chevallier P.

Eur J Haematol. 2017 Jul;99(1):60-69. doi: 10.1111/ejh.12891. Epub 2017 May 5.

PMID:
28370306
27.

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.

Garnier A, Guillaume T, Peterlin P, Béné MC, Le Bris Y, Dubruille V, Mahé B, Gastinne T, Touzeau C, Blin N, Le Gouill S, Moreau P, Chevallier P.

Bone Marrow Transplant. 2017 Jul;52(7):1063-1064. doi: 10.1038/bmt.2017.60. Epub 2017 Apr 3. No abstract available.

PMID:
28368382
28.

Influence of the Integral Quality Monitor transmission detector on high energy photon beams: A multi-centre study.

Casar B, Pasler M, Wegener S, Hoffman D, Talamonti C, Qian J, Mendez I, Brojan D, Perrin B, Kusters M, Canters R, Pallotta S, Peterlin P.

Z Med Phys. 2017 Sep;27(3):232-242. doi: 10.1016/j.zemedi.2016.10.001. Epub 2017 Mar 21.

PMID:
28336006
29.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.

Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2. No abstract available.

30.

Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

Le Bris Y, Guillaume T, Ménard A, Illiaquer M, Martin J, Malard S, Duquesne A, Peterlin P, Debord C, Robillard N, Eveillard M, Wuillème S, Delaunay J, Mohty M, Garnier A, Moreau P, Béné MC, Chevallier P.

Bone Marrow Transplant. 2017 Jun;52(6):854-858. doi: 10.1038/bmt.2016.364. Epub 2017 Jan 30.

PMID:
28134920
31.

Reducing the dosimetric impact of positional errors in field junctions for craniospinal irradiation using VMAT.

Strojnik A, Méndez I, Peterlin P.

Rep Pract Oncol Radiother. 2016 May-Jun;21(3):232-9. doi: 10.1016/j.rpor.2016.03.002. Epub 2016 Mar 28.

32.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

Mohty M, Malard F, Blaise D, Milpied N, Socié G, Huynh A, Reman O, Yakoub-Agha I, Furst S, Guillaume T, Tabrizi R, Vigouroux S, Peterlin P, El-Cheikh J, Moreau P, Labopin M, Chevallier P.

Haematologica. 2017 Jan;102(1):184-191. doi: 10.3324/haematol.2016.150326. Epub 2016 Aug 25.

33.

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients.

Peterlin P, Guillaume T, Delaunay J, Mohty M, Garnier A, Mahe B, Dubruille V, Blin N, Voldoire M, Touzeau C, Chauvin C, Gastinne T, Béné MC, Le Gouill S, Moreau P, Chevallier P.

Semin Hematol. 2016 Jul;53(3):216-7. doi: 10.1053/j.seminhematol.2016.06.001. Epub 2016 Jun 18. No abstract available.

PMID:
27496314
34.

Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.

Peterlin P, Garnier A, Tissot A, Garandeau C, Houreau-Langlard D, Hourmant M, Vantyghem S, Bonnet A, Guillaume T, Béné MC, Le Gouill S, Moreau P, Chevallier P.

Ann Hematol. 2016 Oct;95(10):1737-8. doi: 10.1007/s00277-016-2754-3. Epub 2016 Jul 27. No abstract available.

PMID:
27465153
35.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Voldoire M, Guillaume T, Peterlin P, Gallas P, Garnier A, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2016 Aug;95(8):1287-93. doi: 10.1007/s00277-016-2705-z. Epub 2016 Jun 14.

PMID:
27297970
36.

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults.

Le Bourgeois A, Peterlin P, Guillaume T, Delaunay J, Duquesne A, Le Gouill S, Moreau P, Mohty M, Campion L, Chevallier P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1473-1479. doi: 10.1016/j.bbmt.2016.04.015. Epub 2016 Apr 24.

37.

Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation.

Desjonqueres A, Illiaquer M, Duquesne A, Le Bris Y, Peterlin P, Guillaume T, Delaunay J, Rialland F, Moreau P, Béné MC, Chevallier P, Eveillard M.

Bone Marrow Transplant. 2016 Aug;51(8):1150-2. doi: 10.1038/bmt.2016.80. Epub 2016 Apr 4. No abstract available.

PMID:
27042846
38.

Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival.

Malard F, Labopin M, Chevallier P, Guillaume T, Duquesne A, Rialland F, Derenne S, Peterlin P, Leauté AG, Brissot E, Gregoire M, Moreau P, Saas P, Gaugler B, Mohty M.

Blood. 2016 Apr 7;127(14):1828-35. doi: 10.1182/blood-2015-12-688739. Epub 2016 Feb 22. Erratum in: Blood. 2018 Oct 18;132(16):1726.

39.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.

Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.

PMID:
26687796
40.

Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases.

Le Bourgeois A, Malard F, Chevallier P, Urbistandoy G, Guillaume T, Delaunay J, Peterlin P, Lemarchand P, Germaud P, Mohty M, Moreau P, Chambellan A.

Bone Marrow Transplant. 2016 Apr;51(4):589-92. doi: 10.1038/bmt.2015.284. Epub 2015 Nov 23. No abstract available.

41.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F, Robillard N, Guillaume T, Delaunay J, Charbonnier A, Pigneux A, Peterlin P, Bené MC, Wegener WA, Goldenberg DM, Dombret H.

Haematologica. 2015 Apr;100(4):e128-31. doi: 10.3324/haematol.2014.120220. Epub 2014 Dec 31. No abstract available.

42.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terré C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H.

Haematologica. 2015 May;100(5):e196-9. doi: 10.3324/haematol.2014.115576. Epub 2014 Dec 31. No abstract available.

43.

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Brissot E, Cahu X, Guillaume T, Delaunay J, Ayari S, Peterlin P, Le Bourgeois A, Harousseau JL, Milpied N, Bene MC, Moreau P, Mohty M, Chevallier P.

Ann Hematol. 2015 Apr;94(4):663-9. doi: 10.1007/s00277-014-2259-x. Epub 2014 Nov 21.

PMID:
25409914
44.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S.

Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.

PMID:
25392158
45.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.

46.

Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults.

Le Bourgeois A, Labopin M, Guillaume T, Delaunay J, Foucher Y, Tessoulin B, Malard F, Ayari S, Peterlin P, Derenne S, Herry P, Cesbron A, Gagne K, Lodé L, Illiaquer M, Imbert-Marcille BM, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Exp Hematol. 2014 Nov;42(11):945-54. doi: 10.1016/j.exphem.2014.07.264. Epub 2014 Jul 26.

PMID:
25072620
47.

Long-lasting HHV-6 reactivation in long-term adult survivors after double umbilical cord blood allogeneic stem cell transplantation.

Illiaquer M, Malard F, Guillaume T, Imbert-Marcille BM, Delaunay J, Le Bourgeois A, Rimbert M, Bressollette-Bodin C, Precupanu C, Ayari S, Peterlin P, Moreau P, Mohty M, Chevallier P.

J Infect Dis. 2014 Aug 15;210(4):567-70. doi: 10.1093/infdis/jiu129. Epub 2014 Mar 4.

PMID:
24596281
48.

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT.

Tessoulin B, Delaunay J, Chevallier P, Loirat M, Ayari S, Peterlin P, Le Gouill S, Gastinne T, Moreau P, Mohty M, Guillaume T.

Bone Marrow Transplant. 2014 Apr;49(4):567-71. doi: 10.1038/bmt.2013.233. Epub 2014 Feb 3.

PMID:
24488048
49.

On multichannel film dosimetry with channel-independent perturbations.

Méndez I, Peterlin P, Hudej R, Strojnik A, Casar B.

Med Phys. 2014 Jan;41(1):011705. doi: 10.1118/1.4845095.

PMID:
24387497
50.

Partitioning of oleic acid into phosphatidylcholine membranes is amplified by strain.

Mally M, Peterlin P, Svetina S.

J Phys Chem B. 2013 Oct 10;117(40):12086-94. doi: 10.1021/jp404135g. Epub 2013 Sep 26.

PMID:
24000876

Supplemental Content

Loading ...
Support Center